Ottmann OG - Search Results

1

Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia.

Ottmann OG, Müller-Tidow C, Krämer A, Schlenk RF, Lübbert M, Bug G, Krug U, Bochtler T, Voss F, Taube T, Liu D, Garin-Chesa P, Döhner H. Ottmann OG, et al. Br J Haematol. 2019 Mar;184(6):1018-1021. doi: 10.1111/bjh.15204. Epub 2018 Jun 8. Br J Haematol. 2019. PMID: 29882583 Free article. Clinical Trial. No abstract available.

2

Interleukin 3 improves the ex vivo expansion of primitive human cord blood progenitor cells and maintains the engraftment potential of scid repopulating cells.

Rossmanith T, Schröder B, Bug G, Müller P, Klenner T, Knaus R, Hoelzer D, Ottmann OG. Rossmanith T, et al. Among authors: ottmann og. Stem Cells. 2001;19(4):313-20. doi: 10.1634/stemcells.19-4-313. Stem Cells. 2001. PMID: 11463951

3

Rho family small GTPases control migration of hematopoietic progenitor cells into multicellular spheroids of bone marrow stroma cells.

Bug G, Rossmanith T, Henschler R, Kunz-Schughart LA, Schröder B, Kampfmann M, Kreutz M, Hoelzer D, Ottmann OG. Bug G, et al. Among authors: ottmann og. J Leukoc Biol. 2002 Oct;72(4):837-45. J Leukoc Biol. 2002. PMID: 12377954

4

Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).

Wassmann B, Scheuring U, Pfeifer H, Binckebanck A, Käbisch A, Lübbert M, Leimer L, Gschaidmeier H, Hoelzer D, Ottmann OG. Wassmann B, et al. Among authors: ottmann og. Leukemia. 2003 Oct;17(10):1919-24. doi: 10.1038/sj.leu.2403093. Leukemia. 2003. PMID: 14513038 Clinical Trial.

5

Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.

Pfeifer H, Wassmann B, Hofmann WK, Komor M, Scheuring U, Brück P, Binckebanck A, Schleyer E, Gökbuget N, Wolff T, Lübbert M, Leimer L, Gschaidmeier H, Hoelzer D, Ottmann OG. Pfeifer H, et al. Among authors: ottmann og. Clin Cancer Res. 2003 Oct 15;9(13):4674-81. Clin Cancer Res. 2003. PMID: 14581336

6

Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.

Krauter J, Gorlich K, Ottmann O, Lubbert M, Dohner H, Heit W, Kanz L, Ganser A, Heil G. Krauter J, et al. J Clin Oncol. 2003 Dec 1;21(23):4413-22. doi: 10.1200/JCO.2003.03.166. J Clin Oncol. 2003. PMID: 14645432

7

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.

Fiedler W, Serve H, Döhner H, Schwittay M, Ottmann OG, O'Farrell AM, Bello CL, Allred R, Manning WC, Cherrington JM, Louie SG, Hong W, Brega NM, Massimini G, Scigalla P, Berdel WE, Hossfeld DK. Fiedler W, et al. Among authors: ottmann og. Blood. 2005 Feb 1;105(3):986-93. doi: 10.1182/blood-2004-05-1846. Epub 2004 Sep 30. Blood. 2005. PMID: 15459012 Free article. Clinical Trial.

8

Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia.

Romanski A, Bug G, Becker S, Kampfmann M, Seifried E, Hoelzer D, Ottmann OG, Tonn T. Romanski A, et al. Among authors: ottmann og. Exp Hematol. 2005 Mar;33(3):344-52. doi: 10.1016/j.exphem.2004.11.006. Exp Hematol. 2005. PMID: 15730858 Free article.

9

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

Wassmann B, Pfeifer H, Stadler M, Bornhaüser M, Bug G, Scheuring UJ, Brück P, Stelljes M, Schwerdtfeger R, Basara N, Perz J, Bunjes D, Ledderose G, Mahlberg R, Binckebanck A, Gschaidmeier H, Hoelzer D, Ottmann OG. Wassmann B, et al. Among authors: ottmann og. Blood. 2005 Jul 15;106(2):458-63. doi: 10.1182/blood-2004-05-1746. Epub 2005 Apr 7. Blood. 2005. PMID: 15817679 Free article. Clinical Trial.

10

Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.

Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K, Romanski A, Kramer OH, Kampfmann M, Hoelzer D, Neubauer A, Ruthardt M, Ottmann OG. Bug G, et al. Among authors: ottmann og. Cancer. 2005 Dec 15;104(12):2717-25. doi: 10.1002/cncr.21589. Cancer. 2005. PMID: 16294345 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

305 results

Search Page